Success Metrics

Clinical Success Rate
100.0%

Based on 31 completed trials

Completion Rate
100%(31/31)
Active Trials
1(3%)
Results Posted
35%(11 trials)

Phase Distribution

Ph phase_3
14
44%
Ph phase_4
14
44%
Ph phase_2
3
9%

Phase Distribution

0

Early Stage

3

Mid Stage

28

Late Stage

Phase Distribution31 total trials
Phase 2Efficacy & side effects
3(9.7%)
Phase 3Large-scale testing
14(45.2%)
Phase 4Post-market surveillance
14(45.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

31 of 31 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

32

all time

Status Distribution
Active(1)
Completed(31)

Detailed Status

Completed31
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (9.7%)
Phase 314 (45.2%)
Phase 414 (45.2%)

Trials by Status

recruiting13%
completed3197%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT04085172Phase 4

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Completed
NCT05159687Phase 3

Study of Atomoxetine in the Prevention of Vasovagal Syncope

Recruiting
NCT03154359

Atomoxetine PBPK-PD Clinical Study

Completed
NCT05071612Phase 2

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

Completed
NCT01244490Phase 3

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT01106430Phase 3

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Completed
NCT00506727Phase 4

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Completed
NCT00557960Phase 3

ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD

Completed
NCT00700427Phase 3

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00218322Phase 4

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

Completed
NCT00190775Phase 4

A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00191386Phase 3

Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)

Completed
NCT00191906Phase 4

Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)

Completed
NCT00510276Phase 4

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

Completed
NCT00191945Phase 3

Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00568685Phase 3

Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed
NCT00191698Phase 3

Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD

Completed
NCT00191009Phase 2

Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Completed
NCT00190736Phase 4

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Completed
NCT00485407Phase 3

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

Completed

Drug Details

Intervention Type
DRUG
Total Trials
32